Skip to Main Content

Advertisement

Issue Archive

Table of Contents

BLOOD COMMENTARIES

CLINICAL TRIALS AND OBSERVATIONS

This paper offers the first description of zanubrutinib, a new Bruton tyrosine kinase (BTK) inhibitor with an improved safety profile.

IMMUNOBIOLOGY AND IMMUNOTHERAPY

The results of this study show that chimeric antigen receptor (CAR) T-cell therapy with tisagenlecleucel, a CD19-specific CAR T-cell product, is a feasible option for patients with secondary central nervous system (CNS) diffuse large B-cell lymphoma, with limited toxicity and potential efficacy.

MYELOID NEOPLASIA

The investigators used genomic techniques to interrogate a large series of neutrophilic myeloid neoplasms, including atypical chronic myeloid leukemia, chronic neutrophilic leukemia, and others. They identify unique mutation patterns and a detailed genomic landscape that suggest that the current clinicopathologically defined entities may not be biologically relevant.

THROMBOSIS AND HEMOSTASIS

Factor VIII (FVIII) pharmacokinetic (PK) properties show high interpatient variability in hemophilia A patients. This study evaluates how von Willebrand factor (VWF) genetic variants modify the PKs of FVIII and provides important new mechanistic insights in this area.

TRANSPLANTATION

LETTER TO BLOOD

In a series of elegant studies, the investigators elucidate the developmental path of a TCF3-ZNF384/PTPN11–driven B-cell acute lymphoblastic leukemia (BCP-ALL) with different PTPN11 mutations. Through the analysis of a pair of identical twins, they formally demonstrate for the first time that TCF3-ZNF384 is a primary prenatal event; these results are relevant both for understanding the disease and for potential therapies.

BLOOD WORK

ERRATUM

Close Modal
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close Modal
Close Modal

Advertisement